|Molar Mass||318.373 g·mol−1|
|IUPAC Name||Ethyl 1-(phenylacetyl)-l-prolylglycinate.|
Noopept Tablets is a meticulously formulated research product explicitly designed for scientific exploration, with a clear distinction from any association with human consumption. This tablet form of Noopept serves as a valuable tool for researchers investigating its unique properties and potential benefits in various research domains.
Noopept is a nootropic compound known for its cognitive-enhancing effects. It is recognized for its potential neuroprotective properties and has become a focus of research in the field of neuroscience.
Noopept Tablets finds versatile applications in research domains, providing researchers with a tool to explore its potential benefits. Its applications extend to investigations into cognitive disorders, neuroprotection, and potential implications for diabetes.
Studies suggest that Noopept may have potential applications in addressing cognitive disorders. Research in this domain aims to understand its mechanisms of action and potential therapeutic applications in conditions related to cognitive impairment.
Preliminary research indicates that Noopept may have neuroprotective properties, potentially influencing neuronal survival and function. Investigations into its effects on protecting the brain from damage contribute to understanding its potential applications in neuroprotection.
Research suggests that Noopept may have implications for diabetes, potentially influencing glucose metabolism. Studies exploring its effects on diabetes-related parameters contribute to understanding its potential applications in metabolic health.
Noopept Liquid, developed exclusively for research purposes, provides researchers with a unique avenue for investigating its potential benefits in cognitive disorders, neuroprotection, and potential implications for diabetes. The distinctive characteristics of Noopept make it a promising subject for further exploration in neuroscientific and metabolic research.
- Neznamov GG, Teleshova ES. Comparative studies of Noopept and piracetam in the treatment of patients with mild cognitive disorders in organic brain diseases of vascular and traumatic origin. Neurosci Behav Physiol. 2009 Mar;39(3):311-21. doi: 10.1007/s11055-009-9128-4. PMID: 19234797. [Read More].
- Ostrovskaya RU, Vakhitova YV, Kuzmina USh, Salimgareeva MKh, Zainullina LF, Gudasheva TA, Vakhitov VA, Seredenin SB. Neuroprotective effect of novel cognitive enhancer noopept on AD-related cellular model involves the attenuation of apoptosis and tau hyperphosphorylation. J Biomed Sci. 2014 Aug 6;21(1):74. doi: 10.1186/s12929-014-0074-2. PMID: 25096780; PMCID: PMC4422191. [Read More].
- Perihan Gürbüz, Halil Düzova, Azibe Yildiz, Pınar Çakan, Gül Büşra Kaya, Harika Gözde Gözükara Bağ, Merve Durhan, Cemile Ceren Gül, Aslı Çetin Taşlidere,
Effects of noopept on cognitive functions and pubertal process in rats with diabetes, Life Sciences, Volume 233, 2019, 116698, ISSN 0024-3205, https://doi.org/10.1016/j.lfs.2019.116698. [Read More].